热门资讯> 正文
Neurogene GAAP每股收益为-1.05美元
2025-08-12 04:50
- Neurogene press release (NASDAQ:NGNE): Q2 GAAP EPS of -$1.05.
- Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028.
More on Neurogene
- Neurogene downgraded to Neutral at Baird on regulatory uncertainty
- Seeking Alpha’s Quant Rating on Neurogene
- Historical earnings data for Neurogene
- Financial information for Neurogene
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
